Novartis giving $1.6 billion to get access to two cardio drugsStaff Writer | January 6, 2017
Novartis has agreed to pay up to $1.6 billion to Ionis Pharmaceuticals and its unit Akcea Therapeutics for the rights to two cardiovascular drugs.
Pharma industry Ionis Pharmaceuticals and Akcea Therapeutics
Novartis has also agreed to invest a further $50 million in either Ionis or Akcea within 18 months, as well as payments worth up to $1.4 billion should the drugs prove successful.
Both drugs aim to lower the level of cholesterol-carrying proteins in the blood and reduce the risk of certain cardiovascular diseases developing. ■